| Filed On | Filing |
|---|---|
| 24 Aug 2022 |
8-K/A: Financial Statements and Exhibits
Effective as of August 18, 2022, Precigen, Inc., a Virginia corporation (the “Company”), and its wholly-owned subsidiary, Trans Ova Genetics, L.C., an Iowa limited liability company (“Trans Ova”), completed the previously announced sale ... |
| 06 Feb 2020 |
8-K/A: Financial Statements and Exhibits
On January 31, 2020, Precigen, Inc., formerly known as Intrexon Corporation, (“the Company”) and TS Biotechnology Holdings, LLC (“TS Biotechnology”), a Virginia limited liability company managed by Third Security, LLC (“Third Security”),... |
| 01 Jul 2016 |
8-K/A: Entry into a Material Definitive Agreement
On July 1, 2016, ZIOPHARM amended and restated the Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, or the A&R Certificate of Designation. A summary of the material terms of the amendments follows. |
| 03 Nov 2015 |
8-K/A: Financial Statements and Exhibits
THIS SERVICES AGREEMENT (this “Agreement”) is made and entered into as of the 1st day of November, 2015, by and between Third Security, LLC, a Virginia limited liability company (“THIRD SECURITY”), and Intrexon Corporation, a Virginia co... |
| 28 Oct 2015 |
8-K/A: Financial Statements and Exhibits
There are no material differences between the loss on ordinary activities before taxation and the loss for the financial periods stated above and their historical cost equivalents. |
| 28 Jan 2015 |
8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ... |
| 24 Oct 2014 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined consolidated financial information has been prepared to illustrate the effect of Intrexon Corporation’s (“Intrexon”) acquisition of Trans Ova Genetics, L.C. (“Trans Ova”). |
| 04 Apr 2014 |
8-K/A: Financial Statements and Exhibits
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with... |
| 30 Oct 2013 |
8-K/A: Financial Statements and Exhibits
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with... |
Loading...